
### [NCIT:C9387](http://purl.obolibrary.org/obo/NCIT_C9387)
**Label:** Sarcoma by NCI Grade

**Subclasses:** [NCIT:C5525](http://purl.obolibrary.org/obo/NCIT_C5525) (Prostate Embryonal Rhabdomyosarcoma), [NCIT:C6617](http://purl.obolibrary.org/obo/NCIT_C6617) (Mediastinal Rhabdomyosarcoma), [NCIT:C5847](http://purl.obolibrary.org/obo/NCIT_C5847) (Extrahepatic Bile Duct Embryonal Rhabdomyosarcoma), [NCIT:C9409](http://purl.obolibrary.org/obo/NCIT_C9409) (Epithelioid Sarcoma NCI Grade 2), [NCIT:C5522](http://purl.obolibrary.org/obo/NCIT_C5522) (Prostate Rhabdomyosarcoma), [NCIT:C9404](http://purl.obolibrary.org/obo/NCIT_C9404) (Poorly Differentiated Fibrosarcoma), [NCIT:C7943](http://purl.obolibrary.org/obo/NCIT_C7943) (Adult Alveolar Soft Part Sarcoma), [NCIT:C8797](http://purl.obolibrary.org/obo/NCIT_C8797) (Primary Alveolar Soft Part Sarcoma), [NCIT:C8798](http://purl.obolibrary.org/obo/NCIT_C8798) (Recurrent Alveolar Soft Part Sarcoma), [NCIT:C6378](http://purl.obolibrary.org/obo/NCIT_C6378) (Testicular Rhabdomyosarcoma), [NCIT:C9400](http://purl.obolibrary.org/obo/NCIT_C9400) (Sarcoma NCI Grade 2), [NCIT:C49204](http://purl.obolibrary.org/obo/NCIT_C49204) (Anaplastic Embryonal Rhabdomyosarcoma), [NCIT:C8796](http://purl.obolibrary.org/obo/NCIT_C8796) (Metastatic Alveolar Soft Part Sarcoma), [NCIT:C123735](http://purl.obolibrary.org/obo/NCIT_C123735) (Fusion-Positive Rhabdomyosarcoma), [NCIT:C123736](http://purl.obolibrary.org/obo/NCIT_C123736) (Fusion-Negative Rhabdomyosarcoma), [NCIT:C40225](http://purl.obolibrary.org/obo/NCIT_C40225) (Cervical Alveolar Soft Part Sarcoma), [NCIT:C9130](http://purl.obolibrary.org/obo/NCIT_C9130) (Adult Rhabdomyosarcoma), [NCIT:C123731](http://purl.obolibrary.org/obo/NCIT_C123731) (Fusion-Positive Alveolar Rhabdomyosarcoma), [NCIT:C123732](http://purl.obolibrary.org/obo/NCIT_C123732) (Fusion-Negative Alveolar Rhabdomyosarcoma), [NCIT:C95623](http://purl.obolibrary.org/obo/NCIT_C95623) (Esophageal Rhabdomyosarcoma), [NCIT:C127058](http://purl.obolibrary.org/obo/NCIT_C127058) (Uterine Corpus Rhabdomyosarcoma), [NCIT:C3705](http://purl.obolibrary.org/obo/NCIT_C3705) (Pleomorphic Liposarcoma), [NCIT:C4716](http://purl.obolibrary.org/obo/NCIT_C4716) (Ectomesenchymoma), [NCIT:C3749](http://purl.obolibrary.org/obo/NCIT_C3749) (Alveolar Rhabdomyosarcoma), [NCIT:C27489](http://purl.obolibrary.org/obo/NCIT_C27489) (Spindle Cell Liposarcoma), [NCIT:C128080](http://purl.obolibrary.org/obo/NCIT_C128080) (Vaginal Rhabdomyosarcoma), [NCIT:C3750](http://purl.obolibrary.org/obo/NCIT_C3750) (Alveolar Soft Part Sarcoma), [NCIT:C5610](http://purl.obolibrary.org/obo/NCIT_C5610) (Anal Rhabdomyosarcoma), [NCIT:C3359](http://purl.obolibrary.org/obo/NCIT_C3359) (Rhabdomyosarcoma), [NCIT:C9415](http://purl.obolibrary.org/obo/NCIT_C9415) (Sarcoma NCI Grade 3), [NCIT:C9413](http://purl.obolibrary.org/obo/NCIT_C9413) (Kaposi Sarcoma NCI Grade 2), [NCIT:C9414](http://purl.obolibrary.org/obo/NCIT_C9414) (Kaposi Sarcoma NCI Grade 3), [NCIT:C9411](http://purl.obolibrary.org/obo/NCIT_C9411) (Angiosarcoma NCI Grade 2), [NCIT:C9412](http://purl.obolibrary.org/obo/NCIT_C9412) (Angiosarcoma NCI Grade 3), [NCIT:C27369](http://purl.obolibrary.org/obo/NCIT_C27369) (Adult Pleomorphic Rhabdomyosarcoma), [NCIT:C9410](http://purl.obolibrary.org/obo/NCIT_C9410) (Epithelioid Sarcoma NCI Grade 3), [NCIT:C8092](http://purl.obolibrary.org/obo/NCIT_C8092) (Childhood Alveolar Soft Part Sarcoma), [NCIT:C6508](http://purl.obolibrary.org/obo/NCIT_C6508) (Inflammatory Liposarcoma), [NCIT:C128273](http://purl.obolibrary.org/obo/NCIT_C128273) (Vulvar Alveolar Rhabdomyosarcoma), [NCIT:C5627](http://purl.obolibrary.org/obo/NCIT_C5627) (Rectal Rhabdomyosarcoma), [NCIT:C4258](http://purl.obolibrary.org/obo/NCIT_C4258) (Pleomorphic Rhabdomyosarcoma), [NCIT:C4259](http://purl.obolibrary.org/obo/NCIT_C4259) (Rhabdomyosarcoma with Mixed Embryonal and Alveolar Features), [NCIT:C5464](http://purl.obolibrary.org/obo/NCIT_C5464) (Central Nervous System Rhabdomyosarcoma), [NCIT:C9389](http://purl.obolibrary.org/obo/NCIT_C9389) (Well Differentiated Leiomyosarcoma), [NCIT:C8971](http://purl.obolibrary.org/obo/NCIT_C8971) (Embryonal Rhabdomyosarcoma), [NCIT:C5860](http://purl.obolibrary.org/obo/NCIT_C5860) (Extrahepatic Bile Duct Rhabdomyosarcoma), [NCIT:C9388](http://purl.obolibrary.org/obo/NCIT_C9388) (Sarcoma NCI Grade 1), [NCIT:C9025](http://purl.obolibrary.org/obo/NCIT_C9025) (Well Differentiated Fibrosarcoma), [NCIT:C4250](http://purl.obolibrary.org/obo/NCIT_C4250) (Well Differentiated Liposarcoma), [NCIT:C5190](http://purl.obolibrary.org/obo/NCIT_C5190) (Breast Rhabdomyosarcoma), [NCIT:C40320](http://purl.obolibrary.org/obo/NCIT_C40320) (Vulvar Alveolar Soft Part Sarcoma), [NCIT:C121655](http://purl.obolibrary.org/obo/NCIT_C121655) (Sclerosing Rhabdomyosarcoma), [NCIT:C9390](http://purl.obolibrary.org/obo/NCIT_C9390) (Leiomyosarcoma NCI Grade 3), [NCIT:C9391](http://purl.obolibrary.org/obo/NCIT_C9391) (Leiomyosarcoma NCI Grade 2), [NCIT:C121654](http://purl.obolibrary.org/obo/NCIT_C121654) (Spindle Cell/Sclerosing Rhabdomyosarcoma), [NCIT:C128048](http://purl.obolibrary.org/obo/NCIT_C128048) (Cervical Rhabdomyosarcoma), [NCIT:C6519](http://purl.obolibrary.org/obo/NCIT_C6519) (Spindle Cell Rhabdomyosarcoma), [NCIT:C5834](http://purl.obolibrary.org/obo/NCIT_C5834) (Liver Rhabdomyosarcoma), [NCIT:C8824](http://purl.obolibrary.org/obo/NCIT_C8824) (Recurrent Rhabdomyosarcoma), [NCIT:C5236](http://purl.obolibrary.org/obo/NCIT_C5236) (Ovarian Rhabdomyosarcoma), [NCIT:C45759](http://purl.obolibrary.org/obo/NCIT_C45759) (Cardiac Rhabdomyosarcoma), [NCIT:C5839](http://purl.obolibrary.org/obo/NCIT_C5839) (Gallbladder Rhabdomyosarcoma), 

**Class expressions from DL-Learner:**

- [NCIT:C36105](http://purl.obolibrary.org/obo/NCIT_C36105) (Indolent Clinical Course) 57.14%
- Thing 52.12%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40384](http://purl.obolibrary.org/obo/NCIT_C40384) (Breast Ductal Adenoma))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40383](http://purl.obolibrary.org/obo/NCIT_C40383) (Breast Apocrine Adenoma))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40379](http://purl.obolibrary.org/obo/NCIT_C40379) (Angiosarcoma of the Skin of the Arm after Radical Mastectomy followed by Lymphedema))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40378](http://purl.obolibrary.org/obo/NCIT_C40378) (Post-Radiotherapy Breast Angiosarcoma))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40377](http://purl.obolibrary.org/obo/NCIT_C40377) (Breast Follicular Lymphoma))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40376](http://purl.obolibrary.org/obo/NCIT_C40376) (Breast Burkitt Lymphoma))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40375](http://purl.obolibrary.org/obo/NCIT_C40375) (Breast Diffuse Large B-Cell Lymphoma))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C4037](http://purl.obolibrary.org/obo/NCIT_C4037) (Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40369](http://purl.obolibrary.org/obo/NCIT_C40369) (Sebaceous Breast Carcinoma))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40367](http://purl.obolibrary.org/obo/NCIT_C40367) (Acinic Cell Breast Carcinoma))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40366](http://purl.obolibrary.org/obo/NCIT_C40366) (Oncocytic Breast Carcinoma))) 42.50%
- [NCIT:C53665](http://purl.obolibrary.org/obo/NCIT_C53665) (Intermediate Filaments Present) and (not ([NCIT:C40363](http://purl.obolibrary.org/obo/NCIT_C40363) (Nipple Syringomatous Adenoma))) 42.50%


